Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115811
Title: Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Authors: Bisogno, Gianni 
De Salvo, Gian Luca 
Bergeron, Christophe
Gallego Melcón, Soledad
Merks, Johannes H
Kelsey, Anna
Martelli, Helene
Minard-Colin, Veronique
Orbach, Daniel
Glosli, Heidi
Chisholm, Julia
Casanova, Michela
Zanetti, Ilaria 
Devalck, Christine
Ben-Arush, Myriam
Mudry, Peter
Ferman, Sima
Jenney, Meriel
Ferrari, Andrea
Issue Date: Nov-2019
Journal: The Lancet. Oncology 
Abstract: 
For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival in patients with high-risk rhabdomyosarcoma.
URI: http://hdl.handle.net/20.500.12857/115811
ISSN: 14702045
DOI: 10.1016/S1470-2045(19)30617-5
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

15
checked on May 2, 2021

SCOPUSTM   
Citations

21
checked on Sep 1, 2020

WEB OF SCIENCETM
Citations

53
checked on Dec 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.